Please provide your email address to receive an email when new articles are posted on . Despite advancements in diagnosing and treating patients with neovascular age-related macular degeneration (nAMD ...

Exton, Pennsylvania, July 10, 2025 (GLOBE NEWSWIRE) -- Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape ...

In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end 1 Over 60% of ...

New research examined the effects of cataract surgery on visual acuity and disease activity in patients with nAMD receiving anti-VEGF treatment. The treatment intensity for underlying nAMD remained ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Innovative drug classes and advanced delivery systems ...

Susvimo is the only continuous delivery treatment to provide reliable, long-term vision outcomes in nAMD, the leading cause of vision loss in people over the age of 60With two refills per year, ...

In AVONELLE-X, the largest long-term extension trial in nAMD, disease control and durability were maintained over 4 years, with nearly 80% of patients on extended dosing by study end1 Over 60% of ...

BARCELONA, Spain — Patients who receive a diagnosis of neovascular age-related macular degeneration (nAMD) from their primary care clinician may be less likely to adhere to treatment than those who ...

Basel, 05 September 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the AVONELLE-X and SALWEEN studies of Vabysmo® (faricimab),1,2 presented at the 25th Euretina Congress in ...